According to a “milestone” trial, a new therapy can more than double life expectancy in some lung cancer patients.
The BBC reports how the revolutionary new drug, named Nivolumab, works in conjunction with the body’s defences, preventing cancerous cells from concealing themselves and making them open to attack by the patient’s own immune system.
The findings, published in the American Society of Clinical Oncology, were the result of a study of 582 patients conducted in both the US and Europe. It focused on patients who had advanced lung cancer, and for whom other treatments had been tried or were no longer effective. The study found that those on standard therapy lived, on average, for a further 9.4 months, while those taking the new drug lived for 12.2 months. Within that group, however, some did significantly better, living up to 19.4 months.
Read more: New lung cancer treatment doubles life expectancy